Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20985252 | 0.79 | — | — | |
| SCHEMBL20985243 | 0.79 | — | — | |
| SCHEMBL301224 | 0.79 | — | — | |
| SCHEMBL21645635 | 0.79 | HRH3 (0.45) | HRH3KCNH2FFAR4 | |
| SCHEMBL15655020 | 0.79 | HRH3 (0.40) | HRH3KCNH2FFAR4 | |
| SCHEMBL22615930 | 0.79 | HRH3 (0.40) | HRH3KCNH2FFAR4 | |
| SCHEMBL14728643 | 0.79 | HRH3 (0.45) | HRH3KCNH2FFAR4 | |
| SCHEMBL8165630 | 0.79 | HRH3 (0.37) | HRH3KCNH2FFAR4CYP1A2ALOX15 | |
| SCHEMBL30803106 | 0.76 | SMN1; SMN2 (0.41) | HRH3KCNH2CYP1A2CYP2C19TDP1 | |
| SCHEMBL1634054 | 0.75 | LMNA (0.39) | HRH3KCNH2CYP1A2ALOX15CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163455-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163455-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | HRH3 1020/4885KCNH2 3068/4885FFAR4 38/4885 |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | HRH3 1020/4885KCNH2 3068/4885FFAR4 38/4885 |
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | HRH3 1020/4885KCNH2 3068/4885FFAR4 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.